Vineet Joag1, Onyango Obila2,3, Pawel Gajer4,5, Milcah Carol Scott6, Sara Dizzell7, Michael Humphrys4,5, Kamnoosh Shahabi8, Sanja Huibner8, Brett Shannon1, Wangari Tharao9, Marianne Mureithi2,3, Julius Oyugi2,10, Joshua Kimani10, Charu Kaushic7, Jacques Ravel4,5, Omu Anzala2,3, Rupert Kaul1,8. 1. Department of Immunology, University of Toronto, Ontario, Canada. 2. Department of Medical Microbiology, University of Nairobi. 3. Kenya AIDS Vaccine Initiative, Institute of Clinical Research, Nairobi. 4. Institute for Genome Sciences. 5. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore. 6. Department of Microbiology and Immunology, University of Minnesota, Minneapolis. 7. Department of Pathology and Molecular Medicine, McMaster University, Hamilton. 8. Department of Medicine, University of Toronto. 9. Women's Health in Women's Hands Community Health Centre, Toronto, Ontario. 10. Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
Abstract
BACKGROUND: Genital immunology is a key determinant of human immunodeficiency virus (HIV) susceptibility. Both factors are modulated by bacterial vaginosis (BV) and, to some extent, by Lactobacillus iners, the genital Lactobacillus spp. that predominates in African, Caribbean, and other Black (ACB) women. We conducted a clinical trial to assess the impact of oral metronidazole treatment on the genital immune parameters of HIV acquisition risks in Kenyan women with BV. METHODS: The primary endpoint was ex vivo cervical CD4+ T-cell HIV susceptibility after 1 month; secondary endpoints included genital cytokine/chemokine levels, cervical immune cell populations, and the composition of the cervico-vaginal microbiota by 16S ribosomal RNA gene amplicon sequencing. RESULTS: BV resolved (Nugent score ≤ 3) at 1 month in 20/45 participants, and cervical CD4+ T-cell HIV entry was moderately reduced in all participants, regardless of treatment outcome. Resolution of BV and reduced abundances of BV-associated gram-negative taxa correlated with reduced genital interleukin (IL)-1α/β. However, BV resolution and the concomitant colonization by Lactobacillus iners substantially increased several genital chemokines associated with HIV acquisition, including interferon-γ inducible protein (IP)-10, macrophage inflammatory protein (MIP)-3α, and monokine induced by gamma interferon (MIG). In an independent cohort of ACB women, most of whom were BV-free, vaginal chemokines were again closely linked with L. iners abundance, though not other Lactobacillus spp. CONCLUSIONS: BV treatment reduced genital CD4+ T-cell HIV susceptibility and IL-1 levels, but dramatically increased the genital chemokines that may enhance HIV susceptibility; the latter effect was related to the restoration of an Lactobacillus iners-dominated microbiota. Further studies are needed before treatment of asymptomatic BV can be recommended for HIV prevention in ACB communities.
BACKGROUND: Genital immunology is a key determinant of human immunodeficiency virus (HIV) susceptibility. Both factors are modulated by bacterial vaginosis (BV) and, to some extent, by Lactobacillus iners, the genital Lactobacillus spp. that predominates in African, Caribbean, and other Black (ACB) women. We conducted a clinical trial to assess the impact of oral metronidazole treatment on the genital immune parameters of HIV acquisition risks in Kenyan women with BV. METHODS: The primary endpoint was ex vivo cervical CD4+ T-cell HIV susceptibility after 1 month; secondary endpoints included genital cytokine/chemokine levels, cervical immune cell populations, and the composition of the cervico-vaginal microbiota by 16S ribosomal RNA gene amplicon sequencing. RESULTS: BV resolved (Nugent score ≤ 3) at 1 month in 20/45 participants, and cervical CD4+ T-cell HIV entry was moderately reduced in all participants, regardless of treatment outcome. Resolution of BV and reduced abundances of BV-associated gram-negative taxa correlated with reduced genital interleukin (IL)-1α/β. However, BV resolution and the concomitant colonization by Lactobacillus iners substantially increased several genital chemokines associated with HIV acquisition, including interferon-γ inducible protein (IP)-10, macrophage inflammatory protein (MIP)-3α, and monokine induced by gamma interferon (MIG). In an independent cohort of ACB women, most of whom were BV-free, vaginal chemokines were again closely linked with L. iners abundance, though not other Lactobacillus spp. CONCLUSIONS: BV treatment reduced genital CD4+ T-cell HIV susceptibility and IL-1 levels, but dramatically increased the genital chemokines that may enhance HIV susceptibility; the latter effect was related to the restoration of an Lactobacillus iners-dominated microbiota. Further studies are needed before treatment of asymptomatic BV can be recommended for HIV prevention in ACB communities.
Authors: Jacques Ravel; Pawel Gajer; Zaid Abdo; G Maria Schneider; Sara S K Koenig; Stacey L McCulle; Shara Karlebach; Reshma Gorle; Jennifer Russell; Carol O Tacket; Rebecca M Brotman; Catherine C Davis; Kevin Ault; Ligia Peralta; Larry J Forney Journal: Proc Natl Acad Sci U S A Date: 2010-06-03 Impact factor: 11.205
Authors: Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon Journal: Immunity Date: 2017-01-10 Impact factor: 31.745
Authors: Lindi Masson; Jo-Ann S Passmore; Lenine J Liebenberg; Lise Werner; Cheryl Baxter; Kelly B Arnold; Carolyn Williamson; Francesca Little; Leila E Mansoor; Vivek Naranbhai; Douglas A Lauffenburger; Katharina Ronacher; Gerhard Walzl; Nigel J Garrett; Brent L Williams; Mara Couto-Rodriguez; Mady Hornig; W Ian Lipkin; Anneke Grobler; Quarraisha Abdool Karim; Salim S Abdool Karim Journal: Clin Infect Dis Date: 2015-04-21 Impact factor: 9.079
Authors: H Borgdorff; R Gautam; S D Armstrong; D Xia; G F Ndayisaba; N H van Teijlingen; T B H Geijtenbeek; J M Wastling; J H H M van de Wijgert Journal: Mucosal Immunol Date: 2015-09-09 Impact factor: 7.313
Authors: Daniel J Stieh; Edgar Matias; Huanbin Xu; Angela J Fought; James L Blanchard; Preston A Marx; Ronald S Veazey; Thomas J Hope Journal: Cell Host Microbe Date: 2016-04-13 Impact factor: 21.023
Authors: Cindy M Liu; Jessica L Prodger; Aaron A R Tobian; Alison G Abraham; Godfrey Kigozi; Bruce A Hungate; Maliha Aziz; Fred Nalugoda; Sanjeev Sariya; David Serwadda; Rupert Kaul; Ronald H Gray; Lance B Price Journal: MBio Date: 2017-07-25 Impact factor: 7.867
Authors: Maria L Alcaide; Natasa Strbo; Laura Romero; Deborah L Jones; Violeta J Rodriguez; Kristopher Arheart; Octavio Martinez; Hector Bolivar; Eckhard R Podack; Margaret A Fischl Journal: PLoS One Date: 2016-04-14 Impact factor: 3.240
Authors: Alexander S Zevin; Irene Y Xie; Kenzie Birse; Kelly Arnold; Laura Romas; Garrett Westmacott; Richard M Novak; Stuart McCorrister; Lyle R McKinnon; Craig R Cohen; Romel Mackelprang; Jairam Lingappa; Doug A Lauffenburger; Nichole R Klatt; Adam D Burgener Journal: PLoS Pathog Date: 2016-09-22 Impact factor: 6.823
Authors: Michelle C Sabo; Dara A Lehman; Bingjie Wang; Barbra A Richardson; Sujatha Srinivasan; Lusi Osborn; Daniel Matemo; John Kinuthia; Tina L Fiedler; Matthew M Munch; Alison L Drake; David N Fredricks; Julie Overbaugh; Grace John-Stewart; R Scott McClelland; Susan M Graham Journal: Sex Transm Infect Date: 2019-06-13 Impact factor: 3.519
Authors: Rupert Kaul; Cindy M Liu; Daniel E Park; Ronald M Galiwango; Aaron A R Tobian; Jessica L Prodger Journal: Viruses Date: 2022-05-27 Impact factor: 5.818
Authors: Seth M Bloom; Nomfuneko A Mafunda; Benjamin M Woolston; Matthew R Hayward; Josephine F Frempong; Aaron B Abai; Jiawu Xu; Alissa J Mitchell; Xavier Westergaard; Fatima A Hussain; Nondumiso Xulu; Mary Dong; Krista L Dong; Thandeka Gumbi; F Xolisile Ceasar; Justin K Rice; Namit Choksi; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; David A Relman; Emily P Balskus; Caroline M Mitchell; Douglas S Kwon Journal: Nat Microbiol Date: 2022-03-03 Impact factor: 30.964
Authors: Brett A Tortelli; Warren G Lewis; Jenifer E Allsworth; Nadum Member-Meneh; Lynne R Foster; Hilary E Reno; Jeffrey F Peipert; Justin C Fay; Amanda L Lewis Journal: Am J Obstet Gynecol Date: 2019-10-22 Impact factor: 8.661
Authors: Violetta Florova; Roberto Romero; Adi L Tarca; Jose Galaz; Kenichiro Motomura; Madison M Ahmad; Chaur-Dong Hsu; Richard Hsu; Anna Tong; Jacques Ravel; Kevin R Theis; Nardhy Gomez-Lopez Journal: Cytokine Date: 2020-10-07 Impact factor: 3.861
Authors: Joyce Serebrenik; Tao Wang; Richard Hunte; Sujatha Srinivasan; Jessica McWalters; Gregory K Tharp; Steven E Bosinger; Tina L Fiedler; Jessica M Atrio; Kerry Murphy; Rebecca Barnett; Laurie R Ray; Meighan L Krows; David N Fredricks; Elizabeth Irungu; Kenneth Ngure; Nelly Mugo; Jeanne Marrazzo; Marla J Keller; Betsy C Herold Journal: J Infect Dis Date: 2021-12-15 Impact factor: 5.226
Authors: Jessica L Prodger; Alison G Abraham; Aaron Ar Tobian; Daniel E Park; Maliha Aziz; Kelsey Roach; Ronald H Gray; Lane Buchanan; Godfrey Kigozi; Ronald M Galiwango; Joseph Ssekasanvu; James Nnamutete; Joseph Kagaayi; Rupert Kaul; Cindy M Liu Journal: JCI Insight Date: 2021-04-22
Authors: Christina A Muzny; Paweł Łaniewski; Jane R Schwebke; Melissa M Herbst-Kralovetz Journal: Curr Opin Infect Dis Date: 2020-02 Impact factor: 4.968